| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Outline of Final Research Achievements |
Receptor for advanced glycation end-products (RAGE) is considered linked to the onset and progression of diabetic vascular complications and atherosclerosis. By focusing on target therapies against RAGE, one potentially useful strategy is the conversion of the membrane-bound form of RAGE (mRAGE) to soluble isoform (sRAGE). The ectodomain shedding can increase the sRAGE level and concomitantly decrease mRAGE expression, potentially leading to the prevention and the attenuation of the diabetic vascular diseases. In this study, we screened drug and chemical libraries and identified useful candidates to mediate the ectodomain shedding of RAGE. Our finding will provide promising drugs for treating diabetic patients.
|
